公开(公告)号：US20220348671A1

公开(公告)日：2022-11-03

申请号：US17718622

申请日：2022-04-12

Applicant: Cephalon, Inc.

Inventor： Doris Shim Siew Chen ,  Lynn Dorothy Poulton ,  Adam Clarke ,  David Jose Simon Laine ,  Matthew Pollard ,  Bridget Ann Cooksey ,  Anthony Doyle ,  Jason William Gill

IPC: C07K16/28 ,  A61P11/00

Abstract: Disclosed herein are human antibody molecules that immunospecifically bind to human CXCR2. The disclosed human antibody molecules are potent and selective antagonists of CXCR2 functions and prevent the recruitment of neutrophils into tissues without strongly depleting circulating neutrophil numbers. Pharmaceutical compositions, nucleic acid molecules, vectors, cells, and uses of the disclosed antibodies are also provided.

公开(公告)号：US10906973B2

公开(公告)日：2021-02-02

申请号：US16468960

申请日：2017-12-12

Applicant: National Research Council of Canada ,  Cephalon, Inc.

Inventor： Danica Stanimirovic ,  Traian Sulea ,  Kristin Kemmerich ,  David Wilson ,  Jennifer Stratton ,  Matthew Pollard ,  Adam Clarke

IPC: C07K16/28 ,  A61K47/68

Abstract: The present invention relates, in general, to polypeptides capable of transmigrating the blood-brain barrier, and uses thereof. More specifically, the present invention relates to polypeptides derived by site-directed mutagenesis of an existing antibody fragment and uses thereof, and methods of making such molecules. The polypeptides of the present invention show enhanced blood-brain barrier crossing and brain exposure levels in vitro and in vivo.

公开(公告)号：US20210008035A1

公开(公告)日：2021-01-14

申请号：US16835562

申请日：2020-03-31

Applicant: Cephalon, Inc.

Inventor： Anthony S. Drager ,  Rachel Y. LaBell ,  Piyush R. Patel

IPC: A61K31/4184 ,  A61K9/00 ,  A61K47/10 ,  A61K47/18 ,  A61K47/20 ,  A61K47/22 ,  A61K47/40 ,  A61K9/08

Abstract: Stable liquid formulations of bendamustine, and pharmaceutically acceptable salts thereof, and polar aprotic solvents, are described.

公开(公告)号：US20200323824A1

公开(公告)日：2020-10-15

申请号：US16686751

申请日：2019-11-18

Applicant: Cephalon, Inc.

Inventor： Martin Ian Cooper ,  Laurent D. Courvoisier ,  Mark Eddleston ,  Robert E. McKean

IPC: A61K31/4184 ,  A61K9/14 ,  A61K9/19 ,  C07D235/16 ,  A61K9/00 ,  A61K47/26

Abstract: Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.

公开(公告)号：US20200270339A1

公开(公告)日：2020-08-27

申请号：US16471616

申请日：2017-12-21

Applicant: Cephalon, Inc.

Inventor： David Jose Simon LAINE ,  Matthew POLLARD ,  Anthony Gerard DOYLE ,  Lynn Dorothy POULTON ,  Adam William CLARKE

IPC: C07K16/24 ,  A61P1/00 ,  A61P3/00 ,  A61P37/00 ,  A61P29/02

Abstract: Recombinant antibodies that specifically bind to IL-15 as well as a complex of IL-15 and the IL-15 Receptor-alpha are provided. The antibodies inhibit immune cell proliferation, and are capable of use in the treatment of any autoimmune or inflammatory disease or condition where IL-15 is dysregulated, including Celiac disease.

公开(公告)号：US10201506B2

公开(公告)日：2019-02-12

申请号：US15425421

申请日：2017-02-06

Applicant: Cephalon, Inc.

Inventor： Peter D. Brown ,  Anthony S. Drager

IPC: A61K9/51 ,  A61K38/02 ,  A61K9/50 ,  A61K31/7088 ,  A61K31/4184 ,  A61K9/14 ,  C07D235/16 ,  A61K47/60 ,  A61K47/69

Abstract: The present invention is directed to particles prepared via the polymerization of at least one surfactant and an isocyanate-containing compound. Pharmaceutical compositions prepared using these particles are also described.

公开(公告)号：US20180186873A1

公开(公告)日：2018-07-05

申请号：US15848090

申请日：2017-12-20

Applicant: Cephalon, Inc.

Inventor： Mark Terence Liddament ,  Anthony Doyle ,  Adam Clarke ,  David Jose Simon Laine ,  Bridget Ann Cooksey

IPC: C07K16/24

Abstract: Disclosed herein are fully human antibody molecules that immunospecifically bind to human IL-5. The antibody molecules can bind to human IL-5 with an equilibrium affinity constant (KD) of at least about 40 pM as determined by surface plasmon resonance.

公开(公告)号：US09598377B2

公开(公告)日：2017-03-21

申请号：US14772540

申请日：2014-03-12

Applicant: CEPHALON, INC.

Inventor： Peter D. Brown ,  Anthony S. Drager

IPC: A61K9/50 ,  A61K47/48 ,  A61K31/4184 ,  A61K9/14 ,  C07D235/16

CPC classification number: A61K9/5146 ,  A61K9/145 ,  A61K9/5031 ,  A61K9/5089 ,  A61K31/4184 ,  A61K31/7088 ,  A61K38/02 ,  A61K47/60 ,  A61K47/6935 ,  C07D235/16

Abstract: The present invention is directed to particles prepared via the polymerization of at least one surfactant and an isocyanate-containing compound. Pharmaceutical compositions prepared using these particles are also described.

公开(公告)号：US09238656B2

公开(公告)日：2016-01-19

申请号：US14446411

申请日：2014-07-30

Applicant: Cephalon, Inc.

Inventor： Henry J. Breslin ,  Matthew A. Curry ,  Diane E. Gingrich ,  Keith S. Learn ,  Gregory R. Ott ,  Jason C. Wagner

IPC: C07D493/08 ,  C07D491/107 ,  C07D471/04 ,  A61K31/47 ,  A61K31/437 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61P35/00

CPC classification number: C07D493/08 ,  C07D471/04 ,  C07D491/107

Abstract: This application relates to compounds of the Formula I as defined herein, and/or salts thereof. This application further relates to compositions and methods of using these compounds and/or salts thereof. The compounds of Formula I are useful as ALK and JAK modulators for the treatment of proliferative disorders.

Abstract translation: 本申请涉及本文定义的式I化合物和/或其盐。 本申请还涉及使用这些化合物和/或其盐的组合物和方法。 式I的化合物可用作治疗增殖性疾病的ALK和JAK调节剂。

公开(公告)号：US09034876B2

公开(公告)日：2015-05-19

申请号：US13911465

申请日：2013-06-06

Applicant: Cephalon, Inc.

Inventor： Pawel T. Dobrzanski ,  Matthew M. Seavey

IPC: A61K31/496 ,  A61K45/06

CPC classification number: A61K31/496 ,  A61K45/06 ,  A61K2300/00

Abstract: This application describes and provides a method of treating diseases or disorders characterized by chronic systemic inflammation, such as rheumatoid arthritis, using a compound that inhibits JAK2 kinase.

Abstract translation: 该申请描述并提供了使用抑制JAK2激酶的化合物治疗以慢性全身炎症为特征的疾病或病症如风湿性关节炎的方法。